RxDoctor Payments Data

Hunter Smith, MD

Pulmonary Disease · Boulder, CONPI 1174616130

Payments from drug & device makers

$325in general payments, 2019–2025

Across 14 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$80
  • AstraZeneca$55
  • Insmed, Inc.$42
  • Genentech USA, Inc.$40
  • GSK$40
  • Boston Scientific$28
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$26983%
  • Education$5617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$325 in reported general payments places this provider in the 30th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$50,268
Medicare patients
245
Services billed
647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor12$85,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter104$74,133
Breo ElliptaFluticasone/Vilanterol96$51,786
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$17,378
SymbicortBudesonide/Formoterol Fumarate53$14,862
DuleraMometasone/Formoterol27$9,388
Fluticasone-SalmeterolFluticasone Propion/Salmeterol70$8,403
Advair HfaFluticasone Propion/Salmeterol16$6,289
Albuterol Sulfate HfaAlbuterol Sulfate118$3,766
Wixela InhubFluticasone Propion/Salmeterol17$1,987
Ventolin HfaAlbuterol Sulfate25$1,916
Montelukast Sodium52$523
Fluticasone Propionate21$192
Prednisone28$148
Azithromycin26$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$40$143,296228 claims
AstraZenecaSymbicort$55$14,86253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Boulder

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →